Wegovy and Ozempic: Rising Concerns Over Vision Loss Risk
The popular weight-loss drug Wegovy is facing increased scrutiny due to a significantly higher risk of a rare but serious eye condition compared to its counterpart, Ozempic. New research published in the British Journal of Ophthalmology reveals a potential link between high-dose semaglutide – the active ingredient in Wegovy – and ischemic optic neuropathy (ION), often described as an “eye stroke” that can lead to sudden vision loss.
What is Ischemic Optic Neuropathy?
Ischemic optic neuropathy occurs when blood flow to the optic nerve is abruptly interrupted. This can result in rapid vision loss. While the exact causes are varied, the study suggests a connection to the way Wegovy impacts blood flow and blood pressure.
The FDA Data: Wegovy vs. Ozempic
Researchers analyzed data from the FDA’s adverse event reporting system (FAERS) spanning 2017 to 2024, examining over 30 million notifications. The analysis showed that the risk of developing ION is nearly five times higher in Wegovy users compared to those taking Ozempic. This difference is particularly pronounced in men, who are three times more likely to experience this side effect than women.
Dose Matters: Why Wegovy May Be Different
The study points to the higher doses used in Wegovy, specifically authorized for weight loss, as a potential driver of the increased risk. Rybelsus, a semaglutide pill with slower absorption, showed no reported cases of ION in the analysis. Researchers hypothesize that the higher dose and rapid delivery of Wegovy may contribute to a decrease in blood flow to the optic nerve.
Expert Commentary and Ongoing Vigilance
Independent experts, including ophthalmologists from the University of Southampton, emphasize the necessitate for further investigation. With rising obesity rates globally and the expanding use of these medications – even in younger populations – close monitoring is crucial. The findings underscore a potential safety concern related to dosage that requires urgent prospective evaluation to inform prescribing policies.
Beyond Vision: A Growing Body of Research
This research adds to a growing body of medical literature documenting potential complications associated with obesity medications. While these drugs have demonstrated benefits in areas like dementia and cardiovascular disease, the rapid weight loss and associated hemodynamic changes may have unforeseen consequences for some patients.
Frequently Asked Questions
What are the symptoms of ION?
Sudden, painless vision loss in one or both eyes is the primary symptom. Other symptoms can include blurred vision or difficulty distinguishing colors.
Who is most at risk?
Men taking Wegovy appear to be at a higher risk, but anyone experiencing vision changes while on semaglutide should consult a doctor.
Should I stop taking Wegovy if I’m concerned?
Do not stop taking any medication without first consulting your healthcare provider. They can assess your individual risk factors and determine the best course of action.
Are Ozempic and Rybelsus also linked to vision problems?
The risk appears to be significantly lower with Ozempic and Rybelsus, and Rybelsus showed no reported cases of ION in the study.
Stay informed about the latest health news and research. Explore more articles on our website and subscribe to our newsletter for regular updates.
